Questions About Cancer? 1-800-4-CANCER
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Genitourinary Cancers Steering Committee

The Genitourinary Steering Committee (GUSC) was established in 2008. The GUSC is currently composed of the Steering Committee and three task forces (Prostate Cancer, Bladder Cancer, and Renal Cancer). Members of the GUSC include representatives from the Cooperative Groups with active genitourinary programs, representatives from the prostate, renal, and bladder Specialized Programs of Research Excellence (SPORE) and other translational scientists, community oncologists, biostatisticians, pathologists, patient advocates, and NCI staff.

Mission Statement

The GUSC functions to harmonize an efficient, cost-effective, science-driven, and transparent process that will identify and promote the "Best Science" in genitourinary cancer clinical research by addressing the design and prioritization of phase III trials and large phase II studies.

Roster of Genitourinary Steering Committee (GUSC) members
Robert Dreicer, M.D., Eric Klein, M.D., and Anthony Zietman, M.D., Co-chairs

Task Forces

  • Prostate Cancer: Deborah A. Kuban, M.D., Charles J. Ryan, M.D., Andrew Stephenson, M.D. Co-chairs
  • Bladder Cancer: Dean Bajorin, M.D., Jason A. Efstathiou, M.D., Ph.D. and Seth Lerner, M.D. Co-chairs
  • Renal Cancer: Christopher Kane, M.D., Brian Rini, M.D., Victor Reuter, M.D. Co-chairs

Clinical Trials Planning Meetings (CTPMs)

The Goal of CTPMs is to:

  • identify strategic directions for clinical trials in a specific field
    • reach consensus on the most important clinical trials to conduct;
    • identify portfolio gaps and emerging scientific opportunities;
    • identify innovative trial design opportunities;
  • facilitate innovation and collaboration among the broad oncology community active in the specific cancer under study

List of Clinical Trial Planning Meetings (CTPM) Executive Summaries and Publications


To search all active clinical trials, go to:

CCCT Contact: Abdul Tawab-Amiri, Ph.D.